Background:  The objective of the study was to appraise the total dollar value of human life losses (TDVHL) associated with COVID-19 in Canada. Methods: The net output approach (also known as human capital approach) was applied in the dollar valuation of the 6,062 human life losses associated with COVID-19 in Canada as of 23 May 2020. The economic model was rerun five times: (a) using the nati...

On May 3, 2011, under authority of Clean Air Act (CAA) sections 111 and 112, the EPA proposed both national emission standards for hazardous air pollutants (NESHAP) from coaland oil-fired electric utility steam generating units (EGUs) and standards of performance for fossil-fuelfired electric utility, industrialcommercial-institutional, and small industrial-commercial-institutional steam genera...

The exposure of workers to hot environments is expected to increase as a result of climate change. In order to prevent heat-related illness, it is recommended that workers take breaks during working hours. However, this would lead to reductions in worktime and labor productivity. In this study, we estimate the economic cost of heat-related illness prevention through worker breaks associated wit...

We study the overall topological structure properties of global oil trade network, such as degree, strength, cumulative distribution, information entropy and weight clustering. The structural evolution of the network is investigated as well. We find the global oil import and export networks do not show typical scale-free distribution, but display disassortative property. Furthermore, based on t...

The wide spread of projected temperature changes in climate projections does not predominately originate from uncertainty across climate models; instead it is the broad range of different global socio-economic scenarios and the implied energy production that results in high uncertainty about future climate change. It is therefore important to assess the observational tracking of these scenarios...

UNLABELLED KRAS gain-of-function mutations occur in approximately 30% of all human cancers. Despite more than 30 years of KRAS-focused research and development efforts, no targeted therapy has been discovered for cancers with KRAS mutations. Here, we describe ARS-853, a selective, covalent inhibitor of KRAS(G12C) that inhibits mutant KRAS-driven signaling by binding to the GDP-bound oncoprotein...